382 related articles for article (PubMed ID: 25389802)
1. Review: Influence of ART on HIV genetics.
Simonetti FR; Kearney MF
Curr Opin HIV AIDS; 2015 Jan; 10(1):49-54. PubMed ID: 25389802
[TBL] [Abstract][Full Text] [Related]
2. HIV evolution and diversity in ART-treated patients.
van Zyl G; Bale MJ; Kearney MF
Retrovirology; 2018 Jan; 15(1):14. PubMed ID: 29378595
[TBL] [Abstract][Full Text] [Related]
3. Cells producing residual viremia during antiretroviral treatment appear to contribute to rebound viremia following interruption of treatment.
Aamer HA; McClure J; Ko D; Maenza J; Collier AC; Coombs RW; Mullins JI; Frenkel LM
PLoS Pathog; 2020 Aug; 16(8):e1008791. PubMed ID: 32841299
[TBL] [Abstract][Full Text] [Related]
4. Residual Viremia in Treated HIV+ Individuals.
Conway JM; Perelson AS
PLoS Comput Biol; 2016 Jan; 12(1):e1004677. PubMed ID: 26735135
[TBL] [Abstract][Full Text] [Related]
5. Review: HIV-1 phylogeny during suppressive antiretroviral therapy.
Bale MJ; Kearney MF
Curr Opin HIV AIDS; 2019 May; 14(3):188-193. PubMed ID: 30882485
[TBL] [Abstract][Full Text] [Related]
6. Origin of Rebound Plasma HIV Includes Cells with Identical Proviruses That Are Transcriptionally Active before Stopping of Antiretroviral Therapy.
Kearney MF; Wiegand A; Shao W; Coffin JM; Mellors JW; Lederman M; Gandhi RT; Keele BF; Li JZ
J Virol; 2016 Feb; 90(3):1369-76. PubMed ID: 26581989
[TBL] [Abstract][Full Text] [Related]
7. Impact of Antiretroviral Therapy Duration on HIV-1 Infection of T Cells within Anatomic Sites.
Lee E; von Stockenstrom S; Morcilla V; Odevall L; Hiener B; Shao W; Hartogensis W; Bacchetti P; Milush J; Liegler T; Sinclair E; Hatano H; Hoh R; Somsouk M; Hunt P; Boritz E; Douek D; Fromentin R; Chomont N; Deeks SG; Hecht FM; Palmer S
J Virol; 2020 Jan; 94(3):. PubMed ID: 31723024
[TBL] [Abstract][Full Text] [Related]
8. Lack of concordance between residual viremia and viral variants driving de novo infection of CD4(+) T cells on ART.
Puertas MC; Noguera-Julian M; Massanella M; Pou C; Buzon MJ; Clotet B; Stevenson M; Paredes R; Blanco J; Martinez-Picado J
Retrovirology; 2016 Aug; 13(1):51. PubMed ID: 27484989
[TBL] [Abstract][Full Text] [Related]
9. The role of integration and clonal expansion in HIV infection: live long and prosper.
Anderson EM; Maldarelli F
Retrovirology; 2018 Oct; 15(1):71. PubMed ID: 30352600
[TBL] [Abstract][Full Text] [Related]
10. Early Emergence and Long-Term Persistence of HIV-Infected T-Cell Clones in Children.
Bale MJ; Katusiime MG; Wells D; Wu X; Spindler J; Halvas EK; Cyktor JC; Wiegand A; Shao W; Cotton MF; Hughes SH; Mellors JW; Coffin JM; Van Zyl GU; Kearney MF
mBio; 2021 Apr; 12(2):. PubMed ID: 33832973
[TBL] [Abstract][Full Text] [Related]
11. Impact of Antiretroviral Therapy on HIV-1 Persistence: The Case for Early Initiation.
Hong FF; Mellors JW
AIDS Rev; 2015; 17(2):71-82. PubMed ID: 26035165
[TBL] [Abstract][Full Text] [Related]
12. Clonal Expansion of Human Immunodeficiency Virus-Infected Cells and Human Immunodeficiency Virus Persistence During Antiretroviral Therapy.
Mullins JI; Frenkel LM
J Infect Dis; 2017 Mar; 215(suppl_3):S119-S127. PubMed ID: 28520966
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 Persistence in Children during Suppressive ART.
Katusiime MG; Van Zyl GU; Cotton MF; Kearney MF
Viruses; 2021 Jun; 13(6):. PubMed ID: 34204740
[TBL] [Abstract][Full Text] [Related]
14. The effect of antiretroviral intensification with dolutegravir on residual virus replication in HIV-infected individuals: a randomised, placebo-controlled, double-blind trial.
Rasmussen TA; McMahon JH; Chang JJ; Audsley J; Rhodes A; Tennakoon S; Dantanarayana A; Spelman T; Schmidt T; Kent SJ; Morcilla V; Palmer S; Elliott JH; Lewin SR
Lancet HIV; 2018 May; 5(5):e221-e230. PubMed ID: 29643011
[TBL] [Abstract][Full Text] [Related]
15. Differences in HIV Markers between Infected Individuals Treated with Different ART Regimens: Implications for the Persistence of Viral Reservoirs.
Darcis G; Berkhout B; Pasternak AO
Viruses; 2020 Apr; 12(5):. PubMed ID: 32349381
[TBL] [Abstract][Full Text] [Related]
16. Lack of detectable HIV-1 molecular evolution during suppressive antiretroviral therapy.
Kearney MF; Spindler J; Shao W; Yu S; Anderson EM; O'Shea A; Rehm C; Poethke C; Kovacs N; Mellors JW; Coffin JM; Maldarelli F
PLoS Pathog; 2014 Mar; 10(3):e1004010. PubMed ID: 24651464
[TBL] [Abstract][Full Text] [Related]
17. Establishment and stability of the latent HIV-1 DNA reservoir.
Brodin J; Zanini F; Thebo L; Lanz C; Bratt G; Neher RA; Albert J
Elife; 2016 Nov; 5():. PubMed ID: 27855060
[TBL] [Abstract][Full Text] [Related]
18. Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial).
Stellbrink HJ; van Lunzen J; Westby M; O'Sullivan E; Schneider C; Adam A; Weitner L; Kuhlmann B; Hoffmann C; Fenske S; Aries PS; Degen O; Eggers C; Petersen H; Haag F; Horst HA; Dalhoff K; Möcklinghoff C; Cammack N; Tenner-Racz K; Racz P
AIDS; 2002 Jul; 16(11):1479-87. PubMed ID: 12131185
[TBL] [Abstract][Full Text] [Related]
19. HIV Diversity and Genetic Compartmentalization in Blood and Testes during Suppressive Antiretroviral Therapy.
Miller RL; Ponte R; Jones BR; Kinloch NN; Omondi FH; Jenabian MA; Dupuy FP; Fromentin R; Brassard P; Mehraj V; Chomont N; Poon AFY; Joy JB; Brumme ZL; Routy JP;
J Virol; 2019 Sep; 93(17):. PubMed ID: 31189714
[TBL] [Abstract][Full Text] [Related]
20. Episomal HIV-1 DNA and its relationship to other markers of HIV-1 persistence.
Martinez-Picado J; Zurakowski R; Buzón MJ; Stevenson M
Retrovirology; 2018 Jan; 15(1):15. PubMed ID: 29378611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
